Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Receptor tyrosine kinases in cancer escape from BRAF inhibitors.

Literature DB >> 22565288

Receptor tyrosine kinases in cancer escape from BRAF inhibitors.

Roger S Lo¹.

Abstract

Entities: Disease Gene

Mesh：

Substances：

Year: 2012 PMID： 22565288 PMCID： PMC3367528 DOI： 10.1038/cr.2012.78

Source DB: PubMed Journal: Cell Res ISSN： 1001-0602 Impact factor: 25.617

× No keyword cloud information.

14 in total

1. Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR.

Authors: Anirudh Prahallad; Chong Sun; Sidong Huang; Federica Di Nicolantonio; Ramon Salazar; Davide Zecchin; Roderick L Beijersbergen; Alberto Bardelli; René Bernards
Journal: Nature Date: 2012-01-26 Impact factor: 49.962

2. EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib.

Authors: Ryan B Corcoran; Hiromichi Ebi; Alexa B Turke; Erin M Coffee; Michiya Nishino; Alexandria P Cogdill; Ronald D Brown; Patricia Della Pelle; Dora Dias-Santagata; Kenneth E Hung; Keith T Flaherty; Adriano Piris; Jennifer A Wargo; Jeffrey Settleman; Mari Mino-Kenudson; Jeffrey A Engelman
Journal: Cancer Discov Date: 2012-01-16 Impact factor: 39.397

3. Antitumor activity of BRAF inhibitor vemurafenib in preclinical models of BRAF-mutant colorectal cancer.

Authors: Hong Yang; Brian Higgins; Kenneth Kolinsky; Kathryn Packman; William D Bradley; Richard J Lee; Kathleen Schostack; Mary Ellen Simcox; Scott Kopetz; David Heimbrook; Brian Lestini; Gideon Bollag; Fei Su
Journal: Cancer Res Date: 2011-12-16 Impact factor: 12.701

4. Combinatorial treatments that overcome PDGFRβ-driven resistance of melanoma cells to V600EB-RAF inhibition.

Authors: Hubing Shi; Xiangju Kong; Antoni Ribas; Roger S Lo
Journal: Cancer Res Date: 2011-08-01 Impact factor: 12.701

5. Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K.

Authors: Jessie Villanueva; Adina Vultur; John T Lee; Rajasekharan Somasundaram; Mizuho Fukunaga-Kalabis; Angela K Cipolla; Bradley Wubbenhorst; Xiaowei Xu; Phyllis A Gimotty; Damien Kee; Ademi E Santiago-Walker; Richard Letrero; Kurt D'Andrea; Anitha Pushparajan; James E Hayden; Kimberly Dahlman Brown; Sylvie Laquerre; Grant A McArthur; Jeffrey A Sosman; Katherine L Nathanson; Meenhard Herlyn
Journal: Cancer Cell Date: 2010-12-14 Impact factor: 31.743

6. Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling.

Authors: Nikhil Wagle; Caroline Emery; Michael F Berger; Matthew J Davis; Allison Sawyer; Panisa Pochanard; Sarah M Kehoe; Cory M Johannessen; Laura E Macconaill; William C Hahn; Matthew Meyerson; Levi A Garraway
Journal: J Clin Oncol Date: 2011-03-07 Impact factor: 44.544

7. Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation.

Authors: Ramin Nazarian; Hubing Shi; Qi Wang; Xiangju Kong; Richard C Koya; Hane Lee; Zugen Chen; Mi-Kyung Lee; Narsis Attar; Hooman Sazegar; Thinle Chodon; Stanley F Nelson; Grant McArthur; Jeffrey A Sosman; Antoni Ribas; Roger S Lo
Journal: Nature Date: 2010-11-24 Impact factor: 49.962

8. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib.

Authors: Jeffrey A Sosman; Kevin B Kim; Lynn Schuchter; Rene Gonzalez; Anna C Pavlick; Jeffrey S Weber; Grant A McArthur; Thomas E Hutson; Stergios J Moschos; Keith T Flaherty; Peter Hersey; Richard Kefford; Donald Lawrence; Igor Puzanov; Karl D Lewis; Ravi K Amaravadi; Bartosz Chmielowski; H Jeffrey Lawrence; Yu Shyr; Fei Ye; Jiang Li; Keith B Nolop; Richard J Lee; Andrew K Joe; Antoni Ribas
Journal: N Engl J Med Date: 2012-02-23 Impact factor: 91.245

9. COT drives resistance to RAF inhibition through MAP kinase pathway reactivation.

Authors: Cory M Johannessen; Jesse S Boehm; So Young Kim; Sapana R Thomas; Leslie Wardwell; Laura A Johnson; Caroline M Emery; Nicolas Stransky; Alexandria P Cogdill; Jordi Barretina; Giordano Caponigro; Haley Hieronymus; Ryan R Murray; Kourosh Salehi-Ashtiani; David E Hill; Marc Vidal; Jean J Zhao; Xiaoping Yang; Ozan Alkan; Sungjoon Kim; Jennifer L Harris; Christopher J Wilson; Vic E Myer; Peter M Finan; David E Root; Thomas M Roberts; Todd Golub; Keith T Flaherty; Reinhard Dummer; Barbara L Weber; William R Sellers; Robert Schlegel; Jennifer A Wargo; William C Hahn; Levi A Garraway
Journal: Nature Date: 2010-11-24 Impact factor: 49.962

10. RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E).

Authors: Poulikos I Poulikakos; Yogindra Persaud; Manickam Janakiraman; Xiangju Kong; Charles Ng; Gatien Moriceau; Hubing Shi; Mohammad Atefi; Bjoern Titz; May Tal Gabay; Maayan Salton; Kimberly B Dahlman; Madhavi Tadi; Jennifer A Wargo; Keith T Flaherty; Mark C Kelley; Tom Misteli; Paul B Chapman; Jeffrey A Sosman; Thomas G Graeber; Antoni Ribas; Roger S Lo; Neal Rosen; David B Solit
Journal: Nature Date: 2011-11-23 Impact factor: 49.962

13 in total

1. Concomitant RAS, RET/PTC, or BRAF mutations in advanced stage of papillary thyroid carcinoma.

Authors: Minjing Zou; Essa Y Baitei; Ali S Alzahrani; Faisal S BinHumaid; Dania Alkhafaji; Roua A Al-Rijjal; Brian F Meyer; Yufei Shi
Journal: Thyroid Date: 2014-06-10 Impact factor: 6.568

Review 2. Stamping out RAF and MEK1/2 to inhibit the ERK1/2 pathway: an emerging threat to anticancer therapy.

Authors: R Mandal; S Becker; K Strebhardt
Journal: Oncogene Date: 2015-09-14 Impact factor: 9.867

3. pERK 1/2 inhibit Caspase-8 induced apoptosis in cancer cells by phosphorylating it in a cell cycle specific manner.

Authors: Ranadip Mandal; Monika Raab; Yves Matthess; Sven Becker; Rainald Knecht; Klaus Strebhardt
Journal: Mol Oncol Date: 2013-11-20 Impact factor: 6.603

4. A novel AKT1 mutant amplifies an adaptive melanoma response to BRAF inhibition.

Authors: Hubing Shi; Aayoung Hong; Xiangju Kong; Richard C Koya; Chunying Song; Gatien Moriceau; Willy Hugo; Clarissa C Yu; Charles Ng; Thinle Chodon; Richard A Scolyer; Richard F Kefford; Antoni Ribas; Georgina V Long; Roger S Lo
Journal: Cancer Discov Date: 2013-11-21 Impact factor: 39.397

10. Combinatorial drug screening and molecular profiling reveal diverse mechanisms of intrinsic and adaptive resistance to BRAF inhibition in V600E BRAF mutant melanomas.

Authors: Devin G Roller; Brian Capaldo; Stefan Bekiranov; Aaron J Mackey; Mark R Conaway; Emanuel F Petricoin; Daniel Gioeli; Michael J Weber
Journal: Oncotarget Date: 2016-01-19